Evaluation of Nephrotoxic Properties of Favipiravir Using the RPTEC cell model
| Autor: | V. A. Evteev, I. S. Semenova, N. D. Bunyatyan, A. B. Prokofiev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Безопасность и риск фармакотерапии, Vol 11, Iss 4, Pp 423-429 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2312-7821 2619-1164 |
| DOI: | 10.30895/2312-7821-2023-11-4-423-429 |
| Popis: | Scientific relevance. Favipiravir is an antiviral RNA polymerase inhibitor used to treat COVID-19. An adverse drug reaction associated with the use of favipiravir is renal disorder.Aim. This study aimed to investigate favipiravir nephrotoxicity by assessing its effects on the integrity of a monolayer formed by renal proximal tubular epithelial cells (RPTECs).Materials and methods. This study focused on an RPTEC monolayer culture that was seeded at a density of 6×104 cells/cm2 on plates with membrane inserts with 0.4 μm pores. Favipiravir was added to the plate wells at a concentration of 5, 10, or 15 μg/mL. The nephrotoxicity evaluation relied on measuring the transepithelial electrical resistance (TEER) of the RPTEC monolayer. A TEER value of 120–140 Ω×cm2 was considered an indication of nephrotoxicity.Results. RPTEC incubation with favipiravir led to a dose-dependent decrease in the TEER values. However, the TEER values after 6 days of incubation ranged within 250–280 Ω×cm2 and were above the critical thresholdof 120–140 Ω×cm2.Conclusions. The results of this study indicate that favipiravir has no pronounced effect on the TEER of the RPTEC monolayer. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|